equity raise unlikely due to the bridging loan before R&D tax benefit is received
the real concern and why I believe the selling from Gary and others has been so staunch is because of the news from GSK on their FDA approved myelofibrosis drug
https://pharmaphorum.com/news/gsk-gets-wide-fda-approval-myelofibrosis-drug
PXS great but slow, Big Pharma appears to be working more in-house and only making big investments when significant positive data and analysis is produced by small biotechs for high commercial targets
equity raise unlikely due to the bridging loan before R&D tax...
Add SNT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
3.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $35.82M | |||
| Open | High | Low | Value | Volume |
| 3.0¢ | 3.0¢ | 3.0¢ | $85.29K | 2.843M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 1120000 | 2.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 3.0¢ | 215622 | 1 |
View Market Depth
| Last trade - 11.31am 10/07/2024 (20 minute delay) ? |
| SNT (ASX) Chart |